UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,  DC 20549 

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

December 17, 2014

 

 

Pacific Biosciences of California, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

1380 Willow Road 

Menlo Park,  California 94025 

(Address of principal executive offices, including zip code)

(650) 521-8000

(Registrant’s telephone number, including area code)

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):

 

 

 

 

 

 

 

 

---

 

 

 

 

On December 17, 2014, the board of directors (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) appointed Kathy Ordoñez, age 64, as a Class III director to serve on the Board effective immediately.

 

Ms. Ordoñez served as the Senior Vice President of Diagnostic Solutions of Quest Diagnostics, Inc., a publicly-traded company that provides clinical laboratory services, from May of 2011 to June of 2013.  She previously served in various roles, including Chief Executive Officer, at Celera Corporation, a publicly traded biotechnology company, until its sale to Quest Diagnostics in 2011. Ms. Ordoñez also previously held several senior positions at Hoffmann-La Roche, overseeing the formation of Roche Molecular Systems where she served as President and Chief Executive Officer. Ms. Ordoñez also previously served on the board of AdvaMed, a medical device and diagnostics industry advocacy group. Ms. Ordoñez holds a B.A. in Chemistry and Physics and a Doctorate of Science (Honorary) from Hartwick College 

As previously disclosed in the Company’s proxy statement for the 2014 Annual Meeting of Stockholders, as a non-employee director, Ms. Ordoñez will receive an annual retainer of $35,000. Pursuant to the Company’s outside director equity compensation policy, Ms. Ordoñez was automatically granted a stock option to purchase 35,000 shares of the Company’s common stock on the date of her appointment to the Board.

 

On December 18, 2014, the Company issued a press release announcing the appointment of Ms. Ordoñez to the Board.  A copy of the press release is included as Exhibit 99.1. This information is intended to be furnished under Item 7.01 of Form 8-K and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

 

 

 

---

 

 

 

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Date: December 18, 2014

 

 

---

 

 

EXHIBIT INDEX

 

 

 

---